Clinical and resource-use outcomes of risperidone long-acting injection in recent and long-term diagnosed schizophrenia patients: results from a multinational electronic registry

By Olivares J. M.   Peuskens J.   Pecenak J.   Resseler S.   Jacobs A.   Akhras K. S.  

Current Medical Research and Opinion, Vol. 25, Iss. 9, 2009-09 ,pp. : 2197-2206

Informa Healthcare

Access to resources Recommend Favorite

Cost-effectiveness and budget impact of long-acting risperidone in Portugal: a modeling exercise

By Heeg B. M. S.   Antunes J.   Figueira M. L.   Jara J. M.   Marques Teixeira J.   Palha A. P.   Vaz Serra A.   Buskens E.   Caleo S.   Gouveia-Pinto C.   Van Hout B. A.  

Current Medical Research and Opinion, Vol. 24, Iss. 2, 2008-02 ,pp. : 349-358

Informa Healthcare

Access to resources Recommend Favorite

Clinical evaluation of flufenisal, a long‐acting analgesic

By  

CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol. 11, Iss. 5, 1970-09 ,pp. : 747-754

John Wiley & Sons Inc

Access to resources Recommend Favorite

The impact on schizophrenia-related hospital utilization and costs of switching to long-acting risperidone injections in Sweden

By Willis Michael   Svensson Marianne   Löthgren Mickael   Eriksson Bo   Berntsson Anders   Persson Ulf  

The European Journal of Health Economics, Vol. 11, Iss. 6, 2010-12 ,pp. : 585-594

Springer Publishing Company

Access to resources Recommend Favorite

Risperidone long‐acting injection and 1‐year rehospitalization rate of schizophrenia patients: A retrospective cohort study

By  

PSYCHIATRY AND CLINICAL NEUROSCIENCES, Vol. 69, Iss. 8, 2015-08 ,pp. : 497-503

John Wiley & Sons Inc

Access to resources Recommend Favorite